OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis $0.04 0.00 (-1.36%) As of 08/29/2025 02:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About CV Sciences Stock (OTCMKTS:CVSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CV Sciences alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0452-Week Range$0.02▼$0.05Volume174,266 shsAverage Volume161,450 shsMarket Capitalization$6.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California. Read More CV Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreCVSI MarketRank™: CV Sciences scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CV Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCV Sciences has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCV Sciences does not currently pay a dividend.Dividend GrowthCV Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News SentimentN/A News SentimentCV Sciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.11 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CV Sciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for CVSI on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CV Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of CV Sciences is held by insiders.Read more about CV Sciences' insider trading history. Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVSI Stock News HeadlinesCV Sciences, Inc.: CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & FocusAugust 26, 2025 | finanznachrichten.deCV Sciences, Inc. (CVSI) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 1 at 2:00 AM | Banyan Hill Publishing (Ad)CV Sciences Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comCV Sciences Reports Improved Margins and Positive EBITDAAugust 14, 2025 | msn.comCV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025 | CVSI Stock NewsAugust 8, 2025 | gurufocus.comCV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3 | CVSI Stock NewsJune 23, 2025 | gurufocus.comQ1 2025 CV Sciences Inc Earnings CallMay 16, 2025 | uk.finance.yahoo.comSee More Headlines CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed this year? CV Sciences' stock was trading at $0.0338 on January 1st, 2025. Since then, CVSI stock has increased by 7.1% and is now trading at $0.0362. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) posted its earnings results on Thursday, August, 12th. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $5.13 million for the quarter, compared to analyst estimates of $5.12 million. CV Sciences had a negative net margin of 10.36% and a negative trailing twelve-month return on equity of 80.82%. How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KUSHCO (KSHB), NVIDIA (NVDA) and Organigram Global (OGI). Company Calendar Last Earnings8/12/2021Today9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees70Year Founded2016Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.39 million Net Margins-10.36% Pretax Margin-10.41% Return on Equity-80.82% Return on Assets-19.38% Debt Debt-to-Equity Ratio0.12 Current Ratio1.04 Quick Ratio0.30 Sales & Book Value Annual Sales$15.70 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book3.62Miscellaneous Outstanding Shares184,790,000Free Float182,392,000Market Cap$6.69 million OptionableNot Optionable Beta0.65 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:CVSI) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CV Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.